(MYGN) Myriad Genetics, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(MYGN) Myriad Genetics, Inc. Complete Analysis Pack
Myriad Genetics’ Business Model Canvas: How It Creates Value in Genetic Testing
Unlock the strategic blueprint behind Myriad Genetics, Inc.’s business model. This concise Business Model Canvas reveals how the company creates value in genetic testing, builds key partnerships, and captures revenue in a highly competitive healthcare market. Ideal for investors, analysts, and strategists who want actionable insight—get the full canvas for the complete picture.
Partnerships
Illumina, Inc. collaboration
In FY2025, Myriad Genetics used Illumina sequencing platforms to expand germline and somatic workflows, supporting assay development across oncology and inherited disease testing. The tie-up helps Myriad scale molecular diagnostics on Illumina short-read systems, which remain central to high-throughput next-generation sequencing.
Intermountain Precision Genomics alliance
Myriad Genetics' alliance with Intermountain Precision Genomics extends tumor testing and precision oncology across Intermountain Health's 33 hospitals and about 385 clinics, widening access to somatic testing workflows and clinical interpretation. That reach strengthens Myriad's cancer diagnostics footprint and supports faster, more local treatment decisions for more patients.
Healthcare providers and specialty physicians
Ordering physicians are the gatekeepers for Myriad Genetics, Inc.'s tests: oncologists, OB-GYNs, urologists, and psychiatrists decide when a test fits the patient, so provider trust and workflow fit drive adoption. Myriad's partner base matters because nearly all of its revenue comes from clinical testing, making physician integration a direct growth lever.
Payers and reimbursement organizations
Insurance coverage still drives Myriad Genetics, Inc. test use: CMS covered about 67 million Medicare beneficiaries in 2025, and payer policy can quickly change volume and realized price. Myriad must keep strong evidence files and reimbursement support for each assay, because coverage decisions decide who gets tested and what the company gets paid.
- Payer coverage changes test volume fast
- Evidence packages support reimbursement
- Pricing realization depends on payer mix
Reference labs and clinical research networks
Myriad Genetics, Inc. uses reference labs and clinical research networks to validate assays, generate clinical evidence, and publish outcomes that boost test utility and payer trust. These partnerships also help refine products faster and support market credibility across oncology and women’s health testing.
- Validate tests with external data
- Publish outcomes to build adoption
- Support product development speed
- Strengthen clinical and payer trust
Myriad Genetics’ Key Partners Drive Coverage, Reach, and NGS Growth
Myriad Genetics’ key partners are Illumina, Intermountain Precision Genomics, payers, and clinical networks. In FY2025, the Intermountain tie-up reached 33 hospitals and about 385 clinics, while payer coverage remained critical because CMS served about 67 million Medicare beneficiaries in 2025.
| Partner | Why it matters | FY2025 data |
|---|---|---|
| Illumina | Sequencing backbone | Supports NGS workflows |
| Intermountain | Access and referrals | 33 hospitals, 385 clinics |
| Payers | Coverage and price | CMS: 67M beneficiaries |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for Myriad Genetics, Inc., covering its diagnostics strategy, customers, channels, and revenue drivers.
Customizable Excel Spreadsheet
Condenses Myriad Genetics’ business model into a clear, editable snapshot for quick review and strategy work.
Reference Sources
Provides a clear source trail for Myriad Genetics, Inc., making claims easier to verify and decisions easier to defend.
Activities
Genetic assay development
Myriad Genetics develops DNA and RNA-based diagnostic assays across 6 main areas: hereditary cancer, companion diagnostic, prognostic, prenatal, carrier, and mental health testing. This is the core engine of the business, since continuous assay refinement drives clinical utility, payer access, and recurring test demand.
Clinical laboratory testing
Myriad Genetics, Inc. runs clinical laboratory testing in regulated CLIA/CAP settings, where sample intake, sequencing, analysis, and report release are the core steps. Lab quality drives turnaround time and result accuracy, which matter because the company’s 2025 revenue was driven by high-volume diagnostic testing across its core franchises.
Bioinformatics and variant interpretation
Myriad Genetics analyzes raw genomic data and turns it into clinically actionable reports, with variant classification and algorithmic interpretation driving test utility. This activity links sequence data to treatment and risk insights, which is central to Myriad’s diagnostic value proposition.
Evidence generation and clinical validation
Myriad Genetics, Inc. backs evidence generation with clinical studies that prove medical utility and support reimbursement, because providers and payers need clear outcome data before they adopt a test. Validation also protects regulatory and product credibility, which matters in a market where 1 strong study can shape coverage for thousands of patients.
- Prove medical utility
- Support payer coverage
- Strengthen regulatory trust
Commercialization and physician education
Myriad Genetics, Inc. uses sales teams, clinical specialists, and payer-access work to help physicians order the right test at the right time, which lifts diagnostic utilization. Commercialization is tied to education and reimbursement, so each new guideline, payer win, or doctor training session can turn evidence into test volume.
- Sales drives adoption
- Clinical specialists guide ordering
- Access work supports reimbursement
- Utilization growth follows education
Myriad Genetics: 6 Testing Areas, One Precision Medicine Platform
Myriad Genetics, Inc. focuses on assay development, CLIA/CAP lab testing, and genomic interpretation across 6 testing areas: hereditary cancer, companion diagnostic, prognostic, prenatal, carrier, and mental health. It also runs validation studies and payer-access work, because adoption depends on proof, coverage, and physician use.
| Key activity | FY2025 fact |
|---|---|
| Testing areas | 6 |
| Core lab model | CLIA/CAP |
Full Version Awaits
Business Model Canvas
This preview is a genuine excerpt from the Myriad Genetics, Inc. Business Model Canvas, not a mockup or sample. The document you see here is the exact file you’ll receive after purchase, with the same layout, formatting, and content. Once you complete your order, you’ll get full access to the complete, ready-to-use version.
Resources
Proprietary test portfolio
Myriad Genetics, Inc.’s proprietary test portfolio is the core asset: 9 branded assays, including MyRisk, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Prequel, Foresight, Precise Tumor, and GeneSight, drive differentiation, pricing power, and recurring demand. In FY2024, Company Name reported about $837.5 million in revenue, showing how these tests anchor the business model.
Genomic data and interpretation pipelines
Myriad Genetics, Inc. relies on genomic databases and interpretation pipelines to turn variant calls into clinical reports, and each new test can improve classification quality over time. This data moat is hard to copy fast: the company has spent years building evidence sets across hereditary cancer and other tests, while 2025 demand still centers on higher-margin, data-heavy diagnostics.
Clinical laboratory infrastructure
Myriad Genetics, Inc.'s accredited CLIA/CAP laboratory network is a core resource because it handles sample intake, sequencing, analysis, and reporting in one controlled workflow. Lab capacity directly sets throughput and turnaround time, so it shapes service reliability and the company’s ability to support rising test demand.
Scientific and medical expertise
Myriad Genetics, Inc. depends on molecular biologists, geneticists, bioinformaticians, and clinical specialists to build assays and turn complex variant data into clear medical reports. That expertise also helps keep provider and payer trust high, which matters in a market where test acceptance and reimbursement drive revenue.
- Assay development
- Medical interpretation
- Provider credibility
- Payer confidence
Brand, regulatory, and reimbursement assets
Myriad Genetics, Inc. leans on a known brand in hereditary cancer testing, plus FDA-cleared and companion diagnostic assets like BRACAnalysis CDx and MyChoice CDx, to win trust faster in a crowded market. These regulatory rights and payer ties help move tests into coverage and keep adoption high.
- Brand builds clinician trust.
- Clearances support market access.
- Payer ties drive reimbursement.
That mix is a key resource because diagnostics often sell on evidence, coverage, and workflow fit, not price alone.
Myriad Genetics’ 9 Assays Power $837.5M FY2024 Revenue
Myriad Genetics, Inc.'s key resources are its 9 branded assays, CLIA/CAP labs, and specialist staff, which support test quality, speed, and reimbursement. FY2024 revenue was about $837.5 million, showing how these assets drive the model.
| Key resource | Data |
|---|---|
| Assays | 9 branded tests |
| Revenue | $837.5 million FY2024 |
Value Propositions
Precision oncology decision support
Myriad Genetics’ precision oncology decision support turns molecular test results from 5 core assays, including BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, and Precise Tumor, into clearer treatment choices for cancer care. That matters in a market where cancer still causes nearly 10 million deaths a year worldwide, so better biomarkers help reduce uncertainty in therapy selection.
Hereditary cancer risk assessment
Myriad Genetics, Inc.'s MyRisk hereditary cancer test analyzes 48 genes with DNA sequencing to estimate inherited cancer risk and flag patients who may need tighter screening or preventive steps. By giving families earlier risk signals, it supports faster care decisions; Myriad Genetics, Inc. says the test is used across multiple cancer types and remains central to its hereditary cancer franchise.
Companion diagnostic utility
BRACAnalysis CDx supports treatment decisions for eligible patients with BRCA1/2 variants, helping match the right therapy to the right biomarker. This matters in precision oncology, where 2-gene BRCA testing can guide use of biomarker-linked therapies and reduce trial-and-error care.
Prenatal and carrier screening
Prequel and Foresight give early, noninvasive or preconception risk data that helps guide reproductive decisions. Prequel can screen from 10 weeks’ gestation for common fetal chromosomal abnormalities, while Foresight covers more than 175 inherited conditions, including recessive disease risk, to support informed family planning.
- Prequel: early fetal screening
- Foresight: 175+ carrier risks
Psychiatric medication optimization
GeneSight supports psychiatric medication optimization by helping clinicians match psychotropic drugs more closely to a patient’s genetics, with use across depression, anxiety, and ADHD. Myriad Genetics has said GeneSight has been used in more than 2 million patient tests, aiming to cut trial-and-error prescribing and improve medication fit.
- More precise drug selection
- Used in depression, anxiety, ADHD
- Reduces trial-and-error prescribing
Myriad Genetics Turns DNA Into Actionable Care
Myriad Genetics, Inc. sells decision support that turns genetics into action: oncology tests guide therapy, MyRisk reviews 48 genes for inherited cancer risk, and GeneSight has been used in more than 2 million patient tests to cut trial-and-error prescribing. Prequel and Foresight extend that value into pregnancy and family planning with early fetal screening and 175+ carrier risks.
| Value area | Key data |
|---|---|
| Oncology, hereditary, reproductive, psych | 5 core assays, 48 genes, 2M+ GeneSight tests, 175+ carrier risks |
Customer Relationships
Physician-guided clinical support
Myriad Genetics, Inc. keeps physician-guided clinical support at the core of customer relationships: ordering providers choose tests, and clinical education plus result-interpretation tools help them use the data. In FY2025, this provider-led model supported test adoption across Myriad Genetics, Inc.'s oncology and women’s health portfolio.
Sales and medical liaison engagement
Myriad Genetics, Inc. uses sales and medical liaison teams to teach clinicians and health systems how to order and interpret complex tests, which helps adoption in specialty care where clinical context matters most. This high-touch model supports tests that need expert guidance, especially in oncology and women’s health, and aligns with Myriad Genetics, Inc.’s FY2025 focus on scaling clinical use of its molecular diagnostics.
Insurance and reimbursement support
In FY2025, Myriad Genetics reported about $800 million in revenue, so reimbursement help is not a side task; it supports the core business. By helping patients and providers work through coverage, claims, and appeals, Myriad cuts point-of-service friction in diagnostics, where one denied test can delay care and cash collection.
Patient-facing service support
Patient-facing support is key for Myriad Genetics, Inc. because patients often need help with sample collection, billing, and result delivery. Clear, fast communication lifts trust and can improve test completion in outpatient workflows, where a missed step can delay care.
- Guide sample collection clearly
- Resolve billing questions fast
- Track results delivery closely
Ongoing evidence-based credibility
Customer trust at Myriad Genetics, Inc. rests on clinical evidence and peer-reviewed data, so the company keeps relationships alive by backing tests with validation studies and published support. That evidence base helps clinicians keep using Myriad Genetics, Inc. in practice because it lowers doubt on accuracy, utility, and repeatability.
- Clinical validation builds trust.
- Peer-reviewed data supports adoption.
- Evidence drives repeat use.
Myriad Genetics’ provider-led model drives revenue and test adoption
Myriad Genetics, Inc. keeps customer ties provider-led: physicians order tests, and sales, medical liaison, and reimbursement teams help with interpretation, coverage, and appeals. In FY2025, Myriad Genetics, Inc. generated about $800 million in revenue, so fast support for clinicians and patients directly affects test use and cash collection.
| FY2025 metric | Value |
|---|---|
| Revenue | About $800 million |
| Customer model | Provider-led, high-touch support |
Channels
Physician ordering workflows
Physician ordering drives Myriad Genetics, Inc.’s channel, with healthcare professionals placing tests inside oncology, OB-GYN, urology, and psychiatry workflows. In FY2025, that route remained central to diagnosis and treatment use, supporting clinician-led demand across the company’s core specialty franchises.
Hospital and health system contracts
Myriad Genetics, Inc. uses hospital and health system contracts to reach large institutional buyers, with FY2025 filings showing the company still depends on repeat testing volume to drive revenue. These deals support standardized test ordering and referral paths across health systems, which helps scale and steadies demand.
Reference laboratories and lab networks
Reference laboratories and lab networks extend Myriad Genetics, Inc. tests beyond its own sites, so patients can get access even where in-house testing is limited. They also fit into hospital and clinic ordering flows, which helps keep hereditary cancer and prenatal testing closer to day-to-day care.
Direct commercial sales force
Myriad Genetics, Inc. uses a direct commercial sales force with sales reps and medical science liaisons to train providers and institutions, which helps drive adoption and account management. This field model is key in specialty diagnostics, where clinical education and reimbursement support can shape ordering behavior.
- Direct provider education
- Supports account management
- Best fit for specialty tests
Digital ordering and reporting tools
Myriad Genetics, Inc. uses online portals and electronic workflows to speed sample submission and result delivery, which cuts admin back-and-forth for providers. Digital channels also improve turnaround and make ordering easier across its lab tests and reporting tools.
- Fewer manual steps
- Faster result delivery
- Higher provider convenience
Myriad’s Core Channel: Physician-Led Orders, Backed by Health Systems
Myriad Genetics, Inc. sells mainly through physician orders, so oncology, OB-GYN, urology, and psychiatry workflows stay the core channel. FY2025 still leaned on hospital and health system contracts, plus reference labs and digital portals, to keep test access broad and ordering simple.
| Channel | Role |
|---|---|
| Physicians | Main ordering path |
| Health systems | Repeat volume |
| Portals | Faster orders |
Customer Segments
Oncology patients
Oncology patients with breast, ovarian, prostate, pancreatic, and other cancers are core users of Myriad Genetics, Inc. In 2025, the American Cancer Society projected about 2.0 million new U.S. cancer cases, underscoring the large pool that needs hereditary risk and tumor testing for treatment guidance.
Women’s health and prenatal patients
Myriad Genetics serves pregnant individuals and prospective parents with Prequel and Foresight, which help guide reproductive and fetal-risk decisions. This preventive screening niche matters because the U.S. sees about 3.6 million births a year, keeping demand tied to routine prenatal care and early risk detection.
Psychiatry and behavioral health patients
GeneSight targets psychiatry and behavioral health patients using psychotropic drugs for depression, anxiety, and ADHD, where Myriad Genetics, Inc. says the goal is better outpatient medication optimization. In a U.S. market where about 1 in 5 adults experiences mental illness each year, that segment stays large and recurring.
Specialty physicians and clinics
Myriad Genetics, Inc. sells mainly through specialty physicians and clinics: oncologists, urologists, OB-GYNs, and psychiatrists. These prescribers drive test ordering and readouts, so their clinical habits shape demand and revenue mix; in 2025, that meant a portfolio tied to high-value specialty care.
- Oncologists drive cancer testing demand
- Urologists and OB-GYNs shape women’s health orders
- Psychiatrists influence pharmacogenomic use
Hospitals, health systems, and payers
Hospitals, health systems, and payers are the gatekeepers for Myriad Genetics, Inc. They decide where testing is used, how it is reimbursed, and how much patients pay, so a standard pathway can lift adoption fast.
Health systems can also lock in one diagnostic workflow across many sites, while payers shape coverage rules and prior auth. In the U.S., Medicare alone covers more than 66 million people, so coverage policy can move utilization at scale.
- Gatekeepers set access and reimbursement
- Health systems standardize testing pathways
- Payers drive affordability and volume
Myriad’s Demand Base Spans Oncology, Reproductive Care and Psychiatry
Myriad Genetics, Inc. serves three core customer groups in 2025/2026: oncology patients, reproductive-care patients, and psychiatry patients. Its demand base stays broad, with about 2.0 million new U.S. cancer cases in 2025 and roughly 3.6 million U.S. births a year supporting test use.
| Segment | 2025/2026 cue |
|---|---|
| Oncology | 2.0M new U.S. cases |
| Reproductive | 3.6M births/year |
| Psychiatry | 1 in 5 adults |
Cost Structure
Research and development
Myriad Genetics keeps research and development at the core of its diagnostics model, funding new assays, validation work, and biomarker studies to stay ahead in a fast-moving market. This spend supports future test launches and upgrades, and in FY2025 it remained a key operating cost as the company pushed product development forward.
Laboratory operations
Laboratory operations are a core cost block for Myriad Genetics, Inc.: sequencing, reagents, equipment, sample processing, and quality control all keep lab throughput and accuracy high, so spending stays both variable and fixed. In FY2025, these lab costs sat inside a business that still carried over $800 million in annual revenue scale, showing how much operating spend is needed to run a high-volume diagnostics lab.
Sales and marketing
In fiscal 2025, Myriad Genetics kept sales and marketing heavy because field reps, physician education, and brand work drive test adoption across oncology, women's health, and urology. That spend matters in diagnostics: without broad commercial reach, reimbursement and ordering can stall, even when test demand is clinically strong.
General and administrative
Myriad Genetics, Inc. uses general and administrative spend to run corporate overhead, including finance, HR, legal, and executive management. This public-company layer also funds admin support for growth, so it stays tied to compliance, reporting, and scaling the business.
- Finance, HR, legal, leadership
- Supports public-company duties
- Backs growth and admin scale
Regulatory and reimbursement support
Regulatory and reimbursement support is a fixed drag on Myriad Genetics, Inc.'s cost base because diagnostics need FDA, CLIA, and payer documentation, plus constant clinical evidence updates and billing staff. In 2025, this work stayed essential as the Company had to keep payer access and claims support aligned with changing coverage rules.
- Compliance and evidence costs never stop.
- Payer access adds claims and appeal work.
- Billing ops are a persistent expense.
Myriad Genetics’ FY2025 Cost Engine: R&D, Labs, and Sales Drive the Base
Myriad Genetics, Inc. cost structure in FY2025 was led by R&D, lab operations, and commercial spend, with SG&A and compliance keeping the base heavy. In a business with about $837 million in revenue, these costs reflect a scale-dependent diagnostics model that needs constant test development, lab throughput, and payer support.
| FY2025 cost block | What it funds |
|---|---|
| R&D | Assays and biomarker work |
| Lab ops | Sequencing, reagents, QC |
| Sales and marketing | Physician and payer reach |
| SG&A | Overhead and compliance |
Revenue Streams
Per-test diagnostic fees
Myriad Genetics, Inc. earns per-test diagnostic fees each time a genetic test is ordered across oncology, women’s health, and mental health. In its latest reported year, revenue was about $839 million, and test volume remained the key driver of sales growth.
Insurance reimbursement
Insurance reimbursement is Myriad Genetics, Inc.'s main realized revenue driver, because payer coverage decides how much of the list price turns into cash. In FY2025, net sales were heavily shaped by reimbursement rates and claim approval speed, so weak coverage cuts collections fast.
Companion diagnostic and specialty oncology testing
BRACAnalysis CDx and tumor-related oncology assays drive Myriad Genetics, Inc. specialty revenue because they guide targeted therapy choices, so payers and clinicians see clear clinical value. Companion diagnostics also support stronger pricing power; Myriad’s oncology testing segment is anchored by high-stakes decision use, not low-margin screening.
Prenatal, carrier, and reproductive testing
Prequel and Foresight drive Myriad Genetics, Inc. women’s health revenue by selling prenatal, carrier, and reproductive tests for screening and family-planning decisions. Demand tracks outpatient OB-GYN and maternity visits, and Myriad said these women’s health products remain part of its core growth mix.
- Prequel: prenatal screening
- Foresight: carrier testing
- Outpatient and maternity-led demand
Mental health pharmacogenomics testing
GeneSight is Myriad Genetics, Inc.’s psychiatry testing revenue engine, with more than 2 million patient cases used to help guide medication selection. Demand is tied to outpatient behavioral health adoption, where clinicians use pharmacogenomics to reduce trial-and-error prescribing.
- Psychiatry-focused test sales drive revenue.
- Guides antidepressant and antipsychotic choice.
- Outpatient behavioral health boosts volume.
Myriad Genetics: $839M Revenue Fueled by Reimbursed Testing
Myriad Genetics, Inc. makes most revenue from reimbursed genetic tests, with FY2025 net sales of about $839 million. Oncology, women’s health, and psychiatry tests are the core streams, and cash collection depends on payer coverage and claim approval speed.
| Stream | FY2025 |
|---|---|
| Net sales | $839M |
| Core drivers | Oncology, women’s health, psychiatry |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.